CA2338799A1 - Derives de proteine c - Google Patents

Derives de proteine c Download PDF

Info

Publication number
CA2338799A1
CA2338799A1 CA002338799A CA2338799A CA2338799A1 CA 2338799 A1 CA2338799 A1 CA 2338799A1 CA 002338799 A CA002338799 A CA 002338799A CA 2338799 A CA2338799 A CA 2338799A CA 2338799 A1 CA2338799 A1 CA 2338799A1
Authority
CA
Canada
Prior art keywords
protein
derivative
leu
ser
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002338799A
Other languages
English (en)
Inventor
Bruce Edward Gerlitz
Bryan Edward Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2338799A1 publication Critical patent/CA2338799A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)

Abstract

L'invention concerne de nouveaux dérivés de protéine C. Ces polypeptides conservent l'activité biologique de la protéine C humaine de phénotype sauvage, avec des demi-vies sensiblement plus longues dans le sang humain. Ces polypeptides nécessitent donc une administration moins fréquente que la protéine C humaine de phénotype sauvage, et/ou un dosage inférieur à celle-ci, pour traiter les troubles vasculaires occlusifs, les états d'hypercoagulabilité, les dysfonctionnements thrombotiques et les états pathologiques prédisposant à la thrombose.
CA002338799A 1999-04-30 2000-04-13 Derives de proteine c Abandoned CA2338799A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13180199P 1999-04-30 1999-04-30
US60/131,801 1999-04-30
PCT/US2000/008722 WO2000066754A1 (fr) 1999-04-30 2000-04-13 Dérivés de protéine c

Publications (1)

Publication Number Publication Date
CA2338799A1 true CA2338799A1 (fr) 2000-11-09

Family

ID=22451086

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002338799A Abandoned CA2338799A1 (fr) 1999-04-30 2000-04-13 Derives de proteine c

Country Status (11)

Country Link
EP (1) EP1090130A1 (fr)
JP (1) JP2002542832A (fr)
KR (1) KR20010053345A (fr)
AR (1) AR029627A1 (fr)
AU (1) AU4188500A (fr)
BR (1) BR0006088A (fr)
CA (1) CA2338799A1 (fr)
HU (1) HUP0102444A3 (fr)
IL (1) IL140326A0 (fr)
PE (1) PE20010066A1 (fr)
WO (1) WO2000066754A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9915460A (pt) * 1998-11-20 2001-07-17 Lilly Co Eli Método de tratamento de febre hemorrágica virótica
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
DE60108076T2 (de) * 2000-02-02 2006-03-16 Eli Lilly And Co., Indianapolis Protein c derivate
WO2001059084A1 (fr) 2000-02-11 2001-08-16 Eli Lilly And Company Derives de la proteine c
WO2002028416A1 (fr) * 2000-09-30 2002-04-11 Mochida Pharmaceutical Co., Ltd. Traitements preventifs/remedes associes a l'anemie hemolytique
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
MXPA03003388A (es) * 2000-10-18 2005-03-07 Maxygen Aps Moleculas de proteina c o similares a las de proteina c activadas.
WO2006044294A2 (fr) * 2004-10-14 2006-04-27 Eli Lilly And Company Analogues de la proteine humaine c
WO2023171719A1 (fr) * 2022-03-08 2023-09-14 学校法人自治医科大学 Séquence de protéine c activée

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE163048T1 (de) * 1989-12-29 1998-02-15 Zymogenetics Inc Hybrides protein c
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
DE69735597T2 (de) * 1996-11-08 2006-12-21 Oklahoma Medical Research Foundation, Oklahoma Verwendung eines modifizierten protein-c

Also Published As

Publication number Publication date
WO2000066754A1 (fr) 2000-11-09
HUP0102444A3 (en) 2003-09-29
KR20010053345A (ko) 2001-06-25
BR0006088A (pt) 2001-03-20
HUP0102444A2 (hu) 2001-10-28
JP2002542832A (ja) 2002-12-17
EP1090130A1 (fr) 2001-04-11
AU4188500A (en) 2000-11-17
PE20010066A1 (es) 2001-02-02
IL140326A0 (en) 2002-02-10
AR029627A1 (es) 2003-07-10

Similar Documents

Publication Publication Date Title
US6630138B2 (en) Protein C derivatives
US6693075B1 (en) Modified vitamin K-dependent polypeptides
US6573071B1 (en) Factor X analogues with a modified protease cleavage site
CA2096604C (fr) Derives de proteine c
US20030100506A1 (en) Modified Vitamin K-dependent polypeptides
EP1651252B1 (fr) Variants de proteine c activee avec activite cytoprotectrice normale mais avec activite anticoagulante reduite
SK117099A3 (en) Factor x analogues with a modified protease cleavage site
US20060204489A1 (en) Protein C derivatives
CA2071630C (fr) Proteine c hybride
EP1238065B1 (fr) Analogue de facteur x a activation amelioree
US6841371B2 (en) Protein C derivatives
CA2338799A1 (fr) Derives de proteine c
US6998122B1 (en) Protein C derivatives
MXPA00012789A (en) Protein c derivatives
WO2006044294A2 (fr) Analogues de la proteine humaine c
WO2004044190A2 (fr) Polypeptides de proteine c de type zymogene

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued